Physician profile
Ha Le
NPI 1407410400
$2,255.30
in general payments reported to CMS, 2019-2025
19 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $392 · 2023: $820 · 2024: $510 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $521.49 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $398.82 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $259.32 | 2022-2024 | Ztlido, Elyxyb |
| Smith+Nephew, INC. | $137.59 | 2025 | Collagenase Santyl |
| Nestle Healthcare Nutrition INC. | $114.47 | 2022-2023 | |
| Novo Nordisk INC | $111.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.00 | 2021-2025 | Caplyta |
| Pfizer INC. | $99.15 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $97.14 | 2023-2024 | Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $72.64 | 2022-2023 | Austedo Xr |
| Optinose US, INC. | $64.80 | 2023 | |
| Novartis Pharmaceuticals Corporation | $58.61 | 2023 | |
| Lilly USA, LLC | $47.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.62 | 2021 | |
| Abbott Laboratories | $36.38 | 2023 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.27 | 2024 | Gemtesa |
| Vivus LLC | $22.09 | 2024 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $21.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ha Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.